The tumor microenvironment (TME) is the dynamic ecosystem surrounding a tumor, comprising malignant cells, stromal and immune cells, blood vessels, and the extracellular matrix (ECM). It shapes tumor behavior through reciprocal signaling, metabolic adaptation, and structural remodeling.¹

Once viewed as a passive bystander, the TME is now recognized as an active driver of tumor initiation, progression, metastasis, and therapy resistance. Tumor cells continuously reshape their surroundings, while host cells — fibroblasts, immune populations, endothelial cells, and pericytes — co-evolve to support malignant growth. The composition of the TME varies by tumor type, stage, organ of origin, and patient-specific factors.¹,²

This page focuses on the biology and components of the TME. For a mechanistic overview of how the TME is therapeutically reprogrammed, see our companion page on tumor microenvironment modulation.

Cellular components of the TME

The TME contains malignant cells alongside a diverse network of non-malignant populations that collectively regulate tumor progression, immune evasion, angiogenesis, and metastasis.²

Immune cells

Immune cells in the TME exert context-dependent, dual roles — either restraining or supporting tumor growth. They are broadly divided into adaptive (T cells, B cells) and innate (NK cells, macrophages, neutrophils, dendritic cells) populations.²

T cells

CD8⁺ cytotoxic T cells recognize tumor antigens and drive tumor cell killing, supported by Th1 CD4⁺ helper cells through IL-2 and IFN-γ secretion. In contrast, regulatory T cells (Tregs) suppress anti-tumor immunity and promote tumor growth via inhibitory cytokines and stromal cross-talk.²

T cell distribution defines three immune phenotypes:

• Inflamed: T cells evenly distributed within the tumor
• Excluded: T cells confined to the tumor periphery
• Desert: Tumors lacking T cell infiltration

B cells

B cells contribute through antibody production, antigen presentation, and cytokine secretion. They form tertiary lymphoid structures associated with favorable outcomes in melanoma, breast, and ovarian cancer. Conversely, regulatory B cells secrete IL-10 and TGF-β, fostering immunosuppression and correlating with poor prognosis in bladder, prostate, and renal cancers.²

Natural killer (NK) cells

NK cells eliminate tumor cells via direct cytotoxicity and inflammatory cytokine release. While highly effective against circulating tumor cells, their intratumoral activity is dampened by immunosuppressive signals, inhibitory receptor engagement, metabolic stress, and limited infiltration.²,³

Macrophages

Tumor-associated macrophages (TAMs) regulate immunity, tissue remodeling, and angiogenesis. The TME favors an M2-like, immunosuppressive phenotype driven by hypoxia and cytokines such as IL-4. In breast, lung, and gastric cancers, high TAM infiltration correlates with poor prognosis and supports angiogenesis through perivascular VEGF-A release.²

Neutrophils

Neutrophils play stage-dependent roles. In early tumors, they release reactive oxygen species (ROS) and inflammatory cytokines that promote cancer cell apoptosis. In advanced tumors, they shift toward pro-tumorigenic functions, remodeling the ECM and driving angiogenesis through VEGF and MMP-9.²

Dendritic cells

Dendritic cells (DCs) bridge innate and adaptive immunity by presenting tumor antigens to T cells. Pro-inflammatory signals such as type I interferons, IL-12, and GM-CSF support DC maturation, while immunosuppressive factors (IL-10, TGF-β, VEGF) skew DCs toward a tolerogenic phenotype that fails to elicit effective anti-tumor responses.²

Stromal and structural cells

Cancer-associated fibroblasts (CAFs)

CAFs are central architects of the tumor stroma, derived mainly from tissue-resident fibroblasts but also from endothelial cells, pericytes, adipocytes, and mesenchymal stem cells. Activated by TGF-β, PDGF, and FGF2, they remodel the ECM, promote angiogenesis, support metastasis, and contribute to immune evasion.²

CAF accumulation generally correlates with poor prognosis, though in some breast and lung cancers, dense desmoplasia is associated with improved outcomes — reflecting the functional heterogeneity of CAF subsets.²

Endothelial cells

Vascular endothelial cells mediate angiogenesis, nutrient delivery, and immune trafficking. Once tumors exceed 1–2 mm³, hypoxia-inducible factors (HIFs) drive secretion of pro-angiogenic factors (VEGF, PDGF, EGF). The resulting tumor vasculature is structurally abnormal — leaky, tortuous, and poorly perfused — facilitating intravasation and metastatic dissemination.²

Endothelial cells can also undergo endothelial-to-mesenchymal transition (EndoMT) into CAFs under TGF-β and BMP signaling, further amplifying stromal remodeling.²

Adipocytes

Adipocytes secrete metabolites, hormones, and cytokines that fuel tumor growth. In breast cancer, they release free fatty acids that cancer cells use for energy and lipid biosynthesis. Adipocyte-derived leptin promotes proliferation and macrophage activation, while secreted MMPs contribute to ECM remodeling.²

Stellate cells

Hepatic and pancreatic stellate cells transition from quiescent, vitamin A-storing cells into myofibroblast-like cells upon activation. In hepatocellular carcinoma and pancreatic ductal adenocarcinoma, activated stellate cells drive desmoplasia, ECM deposition, and hypoxia, sustaining tumor progression.²

Non-cellular components of the TME

Non-cellular components provide structural support, mediate cell communication, and shape the biochemical landscape that governs tumor behavior.

Extracellular matrix

The ECM, composed of collagen, fibronectin, elastin, and laminin, can constitute up to 60% of tumor mass. Excessive collagen deposition and fibroblast infiltration produce desmoplasia, a feature linked to poor prognosis. Matrix metalloproteinases (MMPs) remodel ECM proteins, while the ECM itself acts as a reservoir for sequestered growth factors (VEGF, FGF, PDGF, TGF-β).²

Interstitial fluid

Tumor interstitial fluid (TIF) is the local perfusate bathing tumor cells, mediating nutrient and signal exchange between cancer cells and circulation. Nutrient depletion (eg glucose, arginine) and accumulation of suppressive metabolites (lactate, lipids, potassium) reshape cancer cell metabolism and impair effector T cell function while favoring Treg activity.⁴

Extracellular vesicles

Exosomes (30–200 nm) carry proteins, RNA, DNA, and lipids reflecting their cell of origin. Within the TME, they mediate communication between tumor and stromal cells, promote inflammation, support angiogenesis, and condition distant sites for metastasis. Hypoxia enhances exosome production, amplifying CAF conversion and tumor progression.²

Signaling molecules

Cytokines, chemokines, and growth factors orchestrate the soluble communication network of the TME.

Chemokines regulate immune cell trafficking with dual outcomes:

• Anti-tumor: CXCL9, CXCL10, and CCL5 recruit cytotoxic T cells, NK cells, and DCs
• Pro-tumor: CCL2, CCL22, and CXCL12 recruit Tregs, MDSCs, and TAMs, or form barriers that exclude effector T cells⁵,⁶

Cytokines, including interferons, interleukins, TNF, and TGF-β, exert pleiotropic effects on tumor growth, EMT, angiogenesis, and immune modulation.⁷

Growth factors (EGF, PDGF, IGF, FGF, VEGF, TGF-β) drive receptor-mediated signaling cascades that regulate proliferation, survival, and stromal activation.⁷

How the TME drives cancer progression

The TME promotes cancer through interconnected processes: bidirectional cell communication, immune evasion, angiogenesis, EMT, and metastatic dissemination.

Tumor and stromal cells continuously exchange signals through cytokines, chemokines, growth factors, and extracellular vesicles. CAFs secrete FGF and HGF to drive proliferation and therapy resistance, while upregulating MMPs (MMP2, MMP9, MMP14) that degrade collagen and fibronectin to clear paths for invasion.⁸,⁹

Parallel deposition of fibronectin, tenascin-C, and crosslinked collagen, stabilized by lysyl oxidase (LOX), stiffens the ECM, generating mechanotransduction cues that favor cancer cell motility.⁹

MMP2

MMP9

MMP14

Immune evasion

The TME promotes immune escape through coordinated suppression:

• TAMs (M2-like) secrete IL-10 and TGF-β, dampening cytotoxic responses
• MDSCs suppress T and NK cells via arginase-1 (ARG1) and nitric oxide synthase 2 (NOS2)
• Tregs reinforce tolerance through IL-10 and TGF-β
• Tumor cells downregulate MHC expression and upregulate checkpoint ligands such as PD-L1¹⁰

Angiogenesis

Pro-angiogenic factors, predominantly VEGF,drive new blood vessel formation to meet tumor demands. Hypoxia stabilizes HIFs, sustaining a feed-forward loop of vascular expansion. The resulting vessels are disorganized and leaky, paradoxically limiting drug delivery while facilitating tumor cell intravasation.¹⁰

Core hallmarks of cancer

VEGF signaling pathway

Epithelial-to-mesenchymal transition (EMT)

EMT enables epithelial cancer cells to acquire mesenchymal traits — increased motility, invasiveness, and apoptosis resistance. TGF-β acts as a context-dependent regulator, restraining tumor initiation early but driving EMT and metastasis in later stages.¹⁰

Metastasis

Through combined angiogenesis, ECM remodeling, and EMT, the TME enables tumor cells to detach, invade, intravasate, and colonize distant sites. Pre-metastatic niches are conditioned by tumor-secreted factors and exosomes, creating receptive environments at distant orrgans.¹,¹⁰

TME-driven therapy resistance

The TME contributes to multidrug resistance through immune suppression, impaired drug delivery, and support of cancer stem cell (CSC) populations.¹¹

Immune-mediated resistance arises from TAMs, MDSCs, and Tregs that blunt cytotoxic responses and reduce immunotherapy efficacy.

Physical and biochemical barriers include dense, stiffened ECM, elevated interstitial fluid pressure, and abnormal vasculature, which together restrict drug penetration.

Metabolic adaptation — driven by hypoxia and acidosis — stabilizes HIF-1, upregulates glycolysis, and induces P-glycoprotein (MDR1), reducing intracellular drug accumulation.

CSC support is sustained by stromal cytokines (HGF, IL-6) and hypoxia, maintaining quiescent, drug-resistant populations through ABC transporters and enhanced DNA repair.¹¹

Tumor heterogeneity and TME dynamics

Spatial heterogeneity

The TME varies across tumor regions, generating distinct microenvironmental niches. In glioblastoma, EGFR-amplified cells dominate hypoxic zones while PDGFRA-amplified cells localize near vasculature — illustrating how local conditions shape tumor cell phenotype and drug response.¹²

Temporal heterogeneity

The TME evolves continuously in response to tumor growth, therapy, and immune pressure. Cellular composition, gene expression, and metabolic profiles shift over time, contributing to acquired resistance and disease progression.¹³

Cancer stem cell niches

CSC niches integrate tumor cells, stromal cells, ECM, and signaling cues to maintain stemness, self-renewal, and plasticity. Hypoxia (via HIF-1α), EMT regulators (Snail, Twist, Zeb1/2), and core developmental pathways (Notch, Wnt, Hedgehog) sustain CSC populations and underlie tumor relapse after therapy.¹⁴

Emerging dimensions of TME biology

The tumor microbiome

Recent advances have revealed that many tumors previously considered sterile — including breast, lung, liver, and pancreatic cancers — harbor distinct intratumoral microbial communities. These microbes, along with their metabolites, form a tumor microbe microenvironment that influences immune modulation, ROS production, and tumor mutational landscapes. Both pro- and anti-tumorigenic effects have been described, depending on microbial composition and host context.¹⁵

Epigenetic regulation of the TME

Epigenetic mechanisms — DNA methylation, histone modifications, and RNA modifications — shape the function of immune and stromal cells within the TME. These layers of regulation modulate immune cell differentiation, cytokine signaling, and tumor antigen presentation, influencing both tumor progression and responsiveness to therapy.¹⁶

For a focused discussion of how these and other TME features are therapeutically reprogrammed, see our companion page on tumor microenvironment modulation.

Frequently asked questions

References

1. de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374–403.
2. Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–R925.
3. Wu SY, Fu T, Jiang YZ, et al. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.
4. Apiz Saab JJ, Muir A. Tumor interstitial fluid analysis enables the study of microenvironment–cell interactions in cancers. Curr Opin Biotechnol. 2023;83:102970.
5. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572.
6. Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 2022;29(1):10–21.
7. Zhang X, Ma H, Gao Y, et al. The tumor microenvironment: signal transduction. Biomolecules. 2024;14(4):438.
8. Biray Avci C, Goker Bagca B, Nikanfar M, et al. Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications. Front Pharmacol. 2024;15:1442888.
9. Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017;45(1):229–236.
10. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46.